Cure8 research brief
Patients with ulcerative colitis who cannot tolerate 5-ASA need alternative maintenance options. This study suggests azathioprine showed comparable continuation, safety, and endoscopic outcomes whether or not patients were 5-ASA–intolerant.
Adults with ulcerative colitis, clinicians managing UC maintenance therapy, and researchers interested in treatment options for 5-ASA–intolerant patients.
This single-center retrospective cohort posted as an abstract on ResearchSquare compared azathioprine maintenance outcomes in ulcerative colitis patients with versus without intolerance to 5-ASA (mesalamine).
The study included 66 patients (15 5-ASA–intolerant, 51 tolerant) treated between 2014 and 2023 and reported similar long-term azathioprine continuation, adverse-event rates, and endoscopic outcomes between the groups.
Azathioprine discontinuations were driven by relapse and adverse events; when adverse-event discontinuations were excluded, continuation rates appeared higher in the 5-ASA–intolerant group, though differences were not statistically significant. Endoscopic Mayo scores at ≥1 year were reported and did not differ by 5-ASA intolerance.
This report is based on the article abstract provided on ResearchSquare and summarizes its findings without additional external interpretation.
If you are considering azathioprine because of 5-ASA intolerance, discuss with your gastroenterologist: this study suggests azathioprine can be effective and tolerable for many patients, but individual risks (including azathioprine-associated adverse events) and monitoring needs remain important.
This is a single-center retrospective cohort whose content is presented as a posted abstract on ResearchSquare (structured content depth = abstract). Results are preliminary from the study report; broader confirmation from larger, prospective studies would strengthen confidence. Individual treatment decisions require clinician assessment and standard azathioprine monitoring.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Older adults with ulcerative colitis can rarely develop large-vessel giant cell arteritis as an extraintestinal complication.
This case report describes successful use of vedolizumab to treat severe UC in a patient who also had PSC and SLE — a rare and complex combination. Patients and clinicians may find it relevant when considering biologic...
The review links specific therapies and surgical options to outcomes that matter to people with IBD — mucosal healing, lower hospitalizations, and reduced need for surgery — and highlights that combining medical and...
